EvoPAR-Prostate01: Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Condition: Prostate Cancer
Sponsor: AstraZeneca
Full Title
Protocol D9723C00001: A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer
Study Treatment
Saruparib (AZD5305) is an oral PARP1 selective inhibitor that will be given in combination with an androgen-receptor signaling inhibitor and androgen deprivation therapy.
Eligibility/Info
Metastatic HRRm castrate sensitive prostate adenocarcinoma that has not been treated with systemic anticancer therapy.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
